AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026

AngioDynamics (ANGO) will report Q4 and full-year fiscal 2026 results before market open on Tuesday, July 14, 2026, followed by a conference call at 8:00 am ET. This is a scheduled reporting update with no financial performance figures or guidance changes disclosed in the announcement.

Analysis

This is an event-date confirmation, not a thesis change. For a small-cap medtech name like ANGO, the only market-relevant issue into the print is whether management can credibly bridge to better operating leverage; absent that, the stock tends to reprice on guide quality more than on the quarter itself. In the next few days, expect positioning to be driven by short interest and liquidity rather than fundamentals, so the reaction can overshoot in either direction.

The key mechanism is cash burn versus gross-margin durability. If revenue growth is coming from lower-quality mix or promotions, any incremental scale can still fail to translate into EBITDA improvement, which keeps the multiple capped versus better-executing peers in the medtech space. Conversely, a clean guide with stable margins would matter more than a backward-looking beat because it would reduce dilution/financing risk over the next 12-18 months.

The contrarian view is that the bar may be low enough that a modest in-line report is not enough to move the stock sustainably. Consensus often misses how much of the bull case is really a balance-sheet and execution story, not just a revenue story. I would treat this as a watch item into the call: the falsifier is any guidance that implies continued cash consumption without a clear path to positive operating leverage over the next 2-3 quarters.

Key Decisions for Investors

• No pre-earnings directional trade in ANGO: the announcement is not a catalyst by itself; wait for the July 14 call and reaction to guide/cash burn before sizing exposure.
• Set a post-print alert on ANGO for a >10% gap on no guidance change; if the move is purely sentiment-driven, consider fading it after transcript review and confirmation that 2H assumptions are unchanged.
• Use the print as a relative-value watch item versus profitable medtech/adjacent growth names (e.g., BSX, MDT, TMDX): go long the cleaner free-cash-flow compounders if ANGO’s update shows margin pressure persisting for 2-3 quarters.
• If management raises FY26 margin and cash-flow guidance materially, the next 1-3 month trade is a tactical long in ANGO for a squeeze; falsifier is continued dilution risk or another guide-down.